Hydroxychloroquine Indications
Hydroxychloroquine is FDA-approved for the treatment of uncomplicated malaria, prophylaxis of malaria in non-resistant areas, rheumatoid arthritis, systemic lupus erythematosus, and chronic discoid lupus erythematosus. 1
FDA-Approved Indications
Malaria
- Treatment of uncomplicated malaria caused by:
- Plasmodium falciparum
- Plasmodium malariae
- Plasmodium ovale
- Plasmodium vivax 1
- Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported 1
- Begin weekly doses 2 weeks prior to travel
- Continue weekly doses while in endemic area
- Continue for 4 weeks after leaving endemic area
Rheumatologic Conditions
- Rheumatoid arthritis in adults 1
- Systemic lupus erythematosus (SLE) in adults 1
- Chronic discoid lupus erythematosus in adults 1
Dermatologic Applications
- Cutaneous lupus erythematosus (CLE) - effective at 400 mg/day with low incidence of retinopathy 3
Important Limitations of Use
Malaria Limitations
Hydroxychloroquine is NOT recommended for:
- Treatment of complicated malaria 1
- Treatment of chloroquine or hydroxychloroquine-resistant strains 1
- Treatment of malaria acquired in areas with chloroquine resistance 1
- Prophylaxis in geographic areas where chloroquine resistance occurs 1
- Prevention of relapses of P. vivax or P. ovale (not active against hypnozoite liver stage forms) 1
COVID-19
- NOT recommended for COVID-19 treatment based on high-certainty evidence showing no mortality benefit and increased risk of adverse effects 2
Dosing Considerations and Safety
Dosing
- Maximum recommended dose: ≤5.0 mg/kg based on actual body weight to minimize retinal toxicity risk 2
- Rheumatoid arthritis: Initial 400-600 mg daily; maintenance 200-400 mg daily 1
- SLE and discoid lupus: 200-400 mg daily (single or divided doses) 1
Safety Monitoring
Retinal toxicity: The most significant dose-limiting toxicity 2
Dose adjustment: Reduce dose by 25% for eGFR <30 ml/min per 1.73 m² 2
Pregnancy: Considered safe if clinically indicated 2
Common Pitfalls and Caveats
- Retinopathy risk increases with higher doses and longer duration of treatment
- Failure to adjust dose based on ideal body weight can increase toxicity risk
- Inappropriate use for COVID-19 despite evidence against its effectiveness
- Overlooking the need for regular ophthalmologic monitoring in long-term users
- Not recognizing potential cardiac adverse effects including cardiomyopathy and ventricular arrhythmias 1